Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of Chronic Eosinophilic Pneumonia and Allergic Bronchopulmonary Aspergillosis - Case series, Almoosa specialist hospital.

In this case series, we present four patients who had asthma and blood eosinophilia. Two patients were diagnosed with Chronic Eosinophilic Pneumonia (CEP) and the other two with Allergic Bronchopulmonary Aspergillosis (ABPA). Laboratory findings revealed profound peripheral eosinophilia with abnormal chest radiography (alveolar shadows, segmental atelectasis, and cystic changes).

Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.

Objective: To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection.

Methods: This is a retrospective cohort of patients with COVID-19 pneumonia who were treated with favipiravir, versus comparison group that received the standard of care.

Results: A total of 226 patients were included; 110 patients received favipiravir and 116 patients received standard of care.